Peter Kiener
Director/Board Member bei LAVA THERAPEUTICS N.V.
Vermögen: 675 $ am 31.03.2024
Profil
Peter Alec Kiener founded Zyngenia, Inc. in 2009, where he worked as President, Chief Executive Officer & Director from 2009 to 2013.
Dr. Kiener also currently works at Resolve Therapeutics LLC, as Chairman, AbCellera Boston, Inc., as Director, Pieris Pharmaceuticals, Inc., as Independent Director from 2018, Cue Biopharma, Inc., as Independent Director from 2020, LAVA Therapeutics NV, as Non-Executive Director from 2023, Wugen, Inc., as Director, Itolerance, Inc., as Director, Intermediate Capital Group Plc (Private Equity), as Venture Partner, and Bridge Valley Ventures LLP, as Venture Partner.
Dr. Kiener also formerly worked at Cereius, Inc., as Chief Executive Officer from 2019 to 2020, GT Biopharma, Inc., as Director from 2018 to 2019, Receptor BioLogix, Inc., as Director, Adheron Therapeutics, Inc., as Director, Virdante Pharmaceuticals, Inc., as Director, Viral Logic Systems Technology Corp., as Director, Bristol Myers Squibb Co., as Head-Global Research & Development from 1983 to 2001, MedImmune LLC, as Executive Vice President-Research & Development from 2001 to 2009, AstraZeneca PLC, as Executive Vice President in 2009, the University of Oxford, as Principal, the University of North Texas, as Assistant Professor from 1982 to 1983, the University of Massachusetts, as Research Associate from 1978 to 1982, Ambrx, Inc., as Chief Science Officer from 2013 to 2014, and Sucampo Pharmaceuticals LLC, as Chief Scientific Officer from 2014 to 2018.
Dr. Kiener received his doctorate degree in 1978 from the University of Oxford and undergraduate degree in 1973 from the University of Lancaster.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CUE BIOPHARMA, INC.
0,00% | 02.01.2024 | 357 ( 0,00% ) | 675 $ | 31.03.2024 |
| 21.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Peter Kiener
| Unternehmen | Position | Beginn |
|---|---|---|
| CUE BIOPHARMA, INC. | Director/Board Member | 01.04.2020 |
| PIERIS PHARMACEUTICALS, INC. | Director/Board Member | 10.09.2018 |
| LAVA THERAPEUTICS N.V. | Director/Board Member | 01.01.2023 |
Wugen, Inc.
 Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Director/Board Member | - |
Itolerance, Inc.
 Itolerance, Inc. BiotechnologyHealth Technology Itolerance, Inc. is an American biotechnology company that specializes in developing regenerative medicines. The private company was founded by Cameron Gray and is currently led by CEO Anthony J. Japour. | Director/Board Member | - |
Bridge Valley Ventures LLP
 Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Private Equity Investor | - |
AbCellera Boston, Inc.
 AbCellera Boston, Inc. BiotechnologyHealth Technology AbCellera Boston, Inc. produces vaccines for plant, animal, and human diseases. It focuses on the discovery of novel therapeutics for autoimmune disease and pain. The company was founded by Theodore G. Clark in 2004 and is headquartered in Arlington, MA. | Director/Board Member | - |
Resolve Therapeutics LLC
 Resolve Therapeutics LLC BiotechnologyHealth Technology Resolve Therapeutics LLC operates as a biotechnology company. It engages in the development of biotechnology drugs. The firm specializes in treatment of debilitating autoimmune diseases such as Systemic Lupus Erythematous and Sjogren’s syndrome. The company was founded by James Posada in 2010 and is headquartered in Seattle, WA. | Chairman | - |
Intermediate Capital Group Plc (Private Equity)
 Intermediate Capital Group Plc (Private Equity) Investment ManagersFinance Intermediate Capital Group Plc (Private Equity) (ICG) is a private equity division of Intermediate Capital Group Plc founded in 1989. The firm is headquartered in London, United Kingdom. | Private Equity Investor | - |
Ehemalige bekannte Positionen von Peter Kiener
| Unternehmen | Position | Ende |
|---|---|---|
| ░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Peter Kiener
| University of Oxford | Doctorate Degree |
| University of Lancaster | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GT BIOPHARMA, INC. | Health Technology |
| ASTRAZENECA PLC | Health Technology |
| PIERIS PHARMACEUTICALS, INC. | Health Technology |
| CUE BIOPHARMA, INC. | Health Technology |
| LAVA THERAPEUTICS N.V. | Health Technology |
| Private Unternehmen | 15 |
|---|---|
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
Receptor BioLogix, Inc.
 Receptor BioLogix, Inc. BiotechnologyHealth Technology Receptor BioLogix, Inc. provides receptor based biological therapeutics. It develops an intron fusion protein platform for the discovery of novel alternative forms splice variants of human proteins with therapeutic potential. The company was founded by H. Michael Shepard, John P. Adelman and Gail M. Clinton on May 27, 2003 and is headquartered in Mountain View, CA. | Health Technology |
Adheron Therapeutics, Inc.
 Adheron Therapeutics, Inc. BiotechnologyHealth Technology Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA. | Health Technology |
AbCellera Boston, Inc.
AbCellera Boston, Inc. BiotechnologyHealth Technology AbCellera Boston, Inc. produces vaccines for plant, animal, and human diseases. It focuses on the discovery of novel therapeutics for autoimmune disease and pain. The company was founded by Theodore G. Clark in 2004 and is headquartered in Arlington, MA. | Health Technology |
Virdante Pharmaceuticals, Inc.
 Virdante Pharmaceuticals, Inc. Medical DistributorsDistribution Services Virdante Pharmaceuticals, Inc. develops and commercializes drugs for auto-immune and inflammatory disorders. The company's products incorporate a proprietary 'sialic switch' technology to improve the anti-inflammatory properties of antibodies. It was founded in 2008 and is headquartered in Cambridge, MA. | Distribution Services |
Zyngenia, Inc.
 Zyngenia, Inc. Drugstore ChainsRetail Trade Zyngenia, Inc. developed new class of bio-therapeutics. The company was founded by Joseph L. Amprey III, Carlos F. Barbas III and Peter Alec Kiener in 2008 and headquartered in Gaithersburg, MD. | Retail Trade |
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Sucampo Pharmaceuticals, Inc.
 Sucampo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD. | Health Technology |
Viral Logic Systems Technology Corp.
 Viral Logic Systems Technology Corp. Pharmaceuticals: MajorHealth Technology Viral Logic Systems Technology Corp. provides pharmaceutical products and services. It develops treatments for autoimmune, inflammatory diseases and disorders. The company was founded by Steven R. Wiley and Craig A. Smith in 2004 and headquartered in Seattle, WA. | Health Technology |
Intermediate Capital Group Plc (Private Equity)
Intermediate Capital Group Plc (Private Equity) Investment ManagersFinance Intermediate Capital Group Plc (Private Equity) (ICG) is a private equity division of Intermediate Capital Group Plc founded in 1989. The firm is headquartered in London, United Kingdom. | Finance |
Resolve Therapeutics LLC
Resolve Therapeutics LLC BiotechnologyHealth Technology Resolve Therapeutics LLC operates as a biotechnology company. It engages in the development of biotechnology drugs. The firm specializes in treatment of debilitating autoimmune diseases such as Systemic Lupus Erythematous and Sjogren’s syndrome. The company was founded by James Posada in 2010 and is headquartered in Seattle, WA. | Health Technology |
Cereius, Inc.
 Cereius, Inc. BiotechnologyHealth Technology Cereius, Inc. develops novel radio-labeled therapeutics for treating solid tumor brain metastasis. The firm delivers new targeted classes of both radiologic diagnostics and radiotherapeutics for the treatment of cancers in the brain. The company was founded by Kimberly Blackwell and Michael R. Zalutsky in 2017 and is headquartered in Durham, NC. | Health Technology |
Bridge Valley Ventures LLP
Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Finance |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Technology Services |
Itolerance, Inc.
Itolerance, Inc. BiotechnologyHealth Technology Itolerance, Inc. is an American biotechnology company that specializes in developing regenerative medicines. The private company was founded by Cameron Gray and is currently led by CEO Anthony J. Japour. | Health Technology |
